This strategy could be proposed for highly selected patients: in a retrospective study about 103 men with negative PSMA-PET/CT at BCR and followed up for at least one year, Celli et al. reported a higher clinical recurrence-free survival in case of PSA < 0.5 ng/mL and low-grade cancer on RP specimens (ISUP 1 and 2) [43]. This evidence concerns the gene FOLH1 and cancer.